China’s Innovative Drug Industry at a Tipping Point: Xinhua
China’s innovative drug sector has reached a critical inflection point, with record-breaking outbound licensing deals, surging international recognition, and transformative artificial intelligence-powered research capabilities reshaping the industry landscape. In a signed commentary published on June 4, 2026, Xinhua News Agency called for accelerated development of the sector, framing innovative drug development as a cornerstone of China’s strategy for high-level technological self-reliance.
Record-Breaking Deal Activity
The commentary, written by Xinhua reporter Peng Yunjia, highlighted that in the past month alone, multiple cooperation deals involving Chinese innovative drug companies reached a total potential transaction value exceeding $100 billion. This surge follows an extraordinary first quarter of 2026, during which China’s innovative drug outbound licensing (BD) transaction total exceeded $600 billion — approaching half of the full-year 2025 total of over $1,300 billion, according to Jiemian News.
Three mega-deals exceeding $10 billion each were signed in the first half of 2026: Hengrui Medicine’s $15.2 billion partnership with Bristol Myers Squibb, Shiyao Group’s (CSPC) $18.5 billion deal with AstraZeneca, and Innovent Biologics’ $10.5 billion agreement with Pfizer, as reported by OFweek.
Regulatory and Approval Milestones
China’s drug regulatory framework has been evolving rapidly to support this transformation. During the 14th Five-Year Plan period (2021-2025), a total of 230 innovative drugs were approved for market in China, with 76 approved in 2025 alone — over 80% of which were domestically developed, according to People’s Daily. As of late May 2026, China had already approved 19 innovative drugs for market this year, of which 15 were domestically developed, data from the National Medical Products Administration (NMPA) shows.
China now accounts for approximately one-third of the world’s innovative drugs under development, the Xinhua commentary noted, marking a dramatic shift from the country’s historical reliance on generic drug manufacturing.
AI Transforming Drug Discovery
Artificial intelligence is fundamentally reshaping pharmaceutical research and development in China. AI-powered drug discovery is reducing early-stage discovery costs by 70% and shortening discovery cycles from 1-2 years to just 3-6 months. Companies like Guangzhou Pharma, using Huawei Ascend computing, have dramatically cut early drug discovery costs, while Hanyu Pharma, combining Huawei’s Pangu molecule model with over 100,000 historical process data records, improved production parameter decision efficiency by 90% and batch pass rate by 22%. Tasly Group has built a traditional Chinese medicine large model trained on over 40 million TCM literature documents and 3.5 million natural product molecular data points.
The NMPA has taken notice. On March 11, 2026, the agency issued a landmark policy opinion on “AI + Drug Regulation” (Document No. 国药监综〔2026〕6号), setting targets for AI integration in drug review, inspection, and monitoring by 2030, as published on the State Council website. The framework envisions a fully integrated AI-drug regulation system by 2030 and a “digital-intelligent, autonomous, secure drug safety governance system” by 2035. Key targets include AI-assisted review and approval, intelligent supervision and inspection, AI-powered testing and monitoring, and AI-enhanced government services.
Clinical Success Stories
The impact of China’s innovative drug push is being felt in hospitals across the country. People’s Daily reported on several cases where domestically developed innovative drugs have transformed patient outcomes. In one case, a stroke patient from Taizhou, Jiangsu, was successfully treated using edaravone dexborneol sublingual tablets — developed by Simcere and approved in December 2024 — which provided neuroprotective benefits during emergency transfer for thrombectomy surgery.
In another case, a 76-year-old patient in Guangzhou suffering from influenza A was successfully treated with onradivir tablets, a domestically developed drug targeting the PB2 subunit of the influenza A virus. Developed over a decade by multiple Guangdong-based entities and approved in May 2025, the drug offers strong efficacy with a favorable safety profile, including no need for dose adjustment in patients with mild-to-moderate renal impairment.
Persistent Challenges
Despite the rapid progress, the Xinhua commentary and other sources identify significant challenges that remain. “It must also be noted that problems such as weak basic research at the source, insufficient global commercialization capabilities, and low efficiency in transforming achievements remain prominent,” the commentary stated.
Chinese companies lack established overseas sales and marketing infrastructure, and converting research findings into marketable products remains slow. The capital market has also shown signs of “good news fatigue” — major deal announcements no longer drive sustained stock price increases, as investors focus on the long and uncertain path from early-stage partnerships to actual revenue generation.
OFweek reported that the semiconductor sector’s strong performance and AI-driven boom have created a significant capital “siphoning effect,” drawing investment away from biotech despite the industry’s fundamental progress. The average upfront payment for outbound BD deals reached $180 million in Q1 2026, up 59% from 2025 and 187% from five years ago, but investors remain skeptical about whether early-stage milestones will translate into commercial success given the 5-8 year average timeline from Phase I trials to market approval.
Regulatory Reform Driving Innovation
China’s drug regulatory environment has undergone sweeping reforms since 2015, when the NMPA (formerly CFDA) began overhauling drug review and approval processes. The agency established four fast-track channels: Breakthrough Therapy Designation, Conditional Approval, Priority Review, and Special Approval. During the 14th Five-Year Plan period, 369 products were included in Breakthrough Therapy programs, and 554 applications entered Priority Review, according to People’s Daily.
The 2019 establishment of the Marketing Authorization Holder (MAH) system further strengthened quality management by making drug marketing authorization holders legally responsible for the entire product lifecycle, from development through manufacturing to post-market surveillance.
Strategic Investment and Policy Support
China’s innovative drug companies are investing heavily in research and development. Listed innovative drug companies reported R&D spending at 15-25% or more of revenue in 2025. Fosun Pharma alone spent RMB 4.303 billion on innovative drug R&D in 2025, according to People’s Daily. The company has licensed multiple products to global partners, including its anti-tumor drug Serplulimab to Eisai of Japan in February 2026 and its GLP-1 product to Pfizer in December 2025.
The 2026 Government Work Report explicitly called for “promoting high-quality development of innovative drugs and medical devices,” signaling continued high-level policy support.
Outlook
The Xinhua commentary positions China’s innovative drug industry at a historic crossroads. With AI-driven efficiency gains, record-breaking international partnerships, and strong government backing, the sector has unprecedented momentum. However, overcoming fundamental weaknesses in basic research and building sustainable global commercial operations will determine whether China can transition from a fast follower to a true global leader in pharmaceutical innovation.
Key questions remain unanswered. Can Chinese companies successfully transition from early-stage licensing deals to building sustainable global commercial operations? Will the capital market’s skepticism toward biotech persist, or will positive clinical data catalysts reverse the trend? How will US-China geopolitical tensions affect Chinese biotech companies’ access to Western markets?
As the commentary concluded: “Every key breakthrough in domestically produced innovative drugs is a vivid practice of high-level technological self-reliance and self-strengthening.” The coming years will test whether China’s innovative drug industry can translate its deal-making momentum into lasting global impact.